Sarah is a Partner at Sofinnova and focuses on biopharmaceutical investments. Sarah currently serves on the Board of Directors of Inozyme (INZY) and a Board Observer for Aeovian, Antiva, Neurana, and NorthSea. Sarah additionally played a central role in Sofinnova’s investments in Apellis (APLS), Pionyr, and YmAbs (YMAB). She previously served as a Board Member for Promedior prior to its acquisition by Roche for up to $1.4B and Board Observer for Akouos (AKUS), NextCure (NXTC) and YmAbs (YMAB).
Prior to joining Sofinnova, Sarah was a postdoctoral fellow in neuroscience at Stanford University. Sarah was previously a Venture Fellow for Canaan Partners. She worked as a research assistant for The Rockefeller University. Before her time at Rockefeller, Sarah was a Clinical Research Coordinator at Massachusetts General Hospital in the Bipolar Clinic and Research Program. Sarah received her Ph.D. in Neuroscience from Yale University, where she was a National Science Foundation Graduate Research Fellow. Sarah is on the board of Stanford’s Neuroscience Translate Oversight Committee.